Southwest Research Institute

US Government As Represented by the Secretary of the Army

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Joseph A McDonough

Hong Dixon

Larry Allen Cabell

Albert M Zwiener

Joseph T Persyn

Darren E Barlow

Neal K Vail

Eliot Mark Slovin

Stephen Thomas Wellinghoff

Michael Gordon Joyce

Kenneth Carson

Paul M Thompson

Rajeshwer Singh Sankhala

Allen Duplantier

Rekha Panchal

Robert Francis Campbell

Nadean M Gutierrez

Jonathan A Bohmann

William E Bauta

Xingguo Cheng

Renukaradhya Gourapura

James D Oxley

Richard Michael Corbett

Darrel W Johnston

Santosh Dhakal

Norma L Cantu

Sandra J Drabik

Andrew P-z Clark

Patricia Underwood

Kevin Fitzpatrick

Maria Lucy Kimmel

Chang Won Lee

The present disclosure is directed at compositions of dimethyl trisulfide (DMTS) suitable for use for treatment of cyanide intoxication. The compositions show particularly useful stability such that the DMTS remains stable for therapeutic use at the identified time periods. The compositions are therefore particularly suitable for use in autoinjectors.

Compositions of dimethyl trisulfide (DMTS) as a cyanide antidote

Inhibitors against SARS-COV-1, SARS-CoV-2 (Covid-19), MERS-CoV, and variants within each, including methods of treating a subject suffering from such respiratory disease.

Inhibitors for coronavirus

Antiviral drugs targeting the N-terminal domain (NTD) of the spike receptor binding domain (RBD) and methods of treating a subject suffering from coronavirus.

Antiviral drugs targeting the N-terminal domain (NTD) of the coronavirus spike receptor binding domain (RBD)

The present disclosure relates to the preparation of polymorphic mixtures of Cepharanthine.2HCl. Mixtures of at least two polymorphic forms can be formed into a mobile liquid phase in organic/aqueous solvent mixtures along with enteric polymer that can be spray dried to produce solid particulate enteric formulations for medicinal drug-treatment applications.

Pharmaceutical salt forms of Cepharanthine and Tetrandrine

The present invention relates to the field of pharmaceutical and vaccine formulations. More specifically, formulations which comprise an antigen comprising a mixture of oligopeptides loaded into liposome nanoparticles, optionally including an adjuvant, to provide an improved immune response.

Liposomal flu vaccine formulation

The present invention is directed at aqueous suspensions of oxime compounds, such as 2-pyridine aldoxime methyl chloride (2-PAM Cl) for autoinjectors. The suspensions are able to provide 600 mg of 2-PAM Cl in one relatively small dose of less than or equal to 1.0 mL, and are particularly useful for placement in relatively small size autoinjectors.

Aqueous suspensions of oximes for autoinjectors

Methods for preparing suspensions of active pharmaceutical ingredients for ensuing drug delivery. The suspension may include a mixture of a relatively low dosage API and a relatively high dosage API or a mixture of an API with a suitable excipient.

Dosage suspensions of active pharmaceutical ingredients

This invention is directed to an apparatus and method for producing microparticles comprising pharmacologically active agents and biodegradable polymers. The apparatus includes a spinning disk containing a reservoir in the center thereof and a flat inclined surface. The apparatus optionally includes serrations and/or a flat surface beneath the periphery of the disk that is parallel to the rotational axis of the disk. The invention is also directed to a method for producing microparticles containing pharmacologically active agents, using the spinning disk apparatus. Formulations containing ophthalmically active agents are provided. Formulations exhibiting zero order release rates are also described.

Biodegradable microparticle pharmaceutical formulations exhibiting improved released rates

The present invention is directed at isoamyl nitrite formulations suitable for use in medicinal applications. The formulations include a composition of isoamyl nitrite in combination with an epoxidized vegetable oil, identified as stabilized isoamyl nitrite. The isoamyl nitrite may also be combined with petrolatum. Methods of treatment of the formulations are applicable to cyanide poisoning, HS poisoning as well as treatment for elevated blood pressure.

Isoamyl nitrite formulations

The present disclosure relates to a method of melt processing an active agent. The method may include encapsulating an active agent in a first polymer material exhibiting a first processing temperature Tand forming capsules including the active agent. The method may also include melt processing the capsules with a second polymer material exhibiting a second processing temperature T, wherein T&#x3e;T.

Processing of heat-sensitive active agents

The present disclosure relates to compositions and methods for producing nanoparticles to provide relatively more rapid delivery of such particles across the blood-brain barrier. The nanoparticles may be formed from bis-quaternary pyridinium-aldoxime salts that may also be of a specific polymorphic structure and which may be formed in either hydrophobic or hydrophilic type liquid media. In addition, the nanoparticle for transport across the blood-brain barrier may comprise a polymeric resin encapsulating a bis-quaternary pyridinium-2-aldoxime salt.

Nanoparticles for drug delivery to the central nervous system

The present disclosure relates to devices and methods for the preparation of amyl nitrite formulations at a point of use location from relatively shelf-stable reagents employing acidic cationic exchange resins.

Point of use generation of amyl nitrite

The present disclosure is directed at a pharmaceutically active nanoparticle suspension that may be optically clear. Such suspensions may be formed by selective dissolution of a pharmaceutically active compound in a first solvent followed by introduction into a second solvent, such as an aqueous medium, without substantial use of surfactants and/or mechanical shear.

Pharmaceutically active nanosuspensions

The present invention relates to two phase systems of a bioactive ingredient in particle form that has limited or no solubility in a liquid medium, which provides stability to the bioactive ingredient that is similar to the bioactive ingredient when in the solid state. The bioactive ingredient may be capable of therapeutically treating for the presence of a cholinesterase inhibitor. The bio active ingredient comprises 1,1'-methlyenebis[4-[(hydroxyimino)methyl]-pyridinium]dimethanesulfonate.

Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts

Bis-quaternary pyridinium-aldoxime salts are disclosed, and their associated polymorphic character, along with their methods of preparation. Such polymorphic salts may then be used for treatment of exposure to cholinesterase inhibitors, such as a phosphorous containing cholinesterase inhibitor type compound.

Growing community of inventors

Helotes, TX, United States of America

Joseph A McDonough